Connelly Deirdre P 4

What Happened Deirdre P. Connelly, a director of Sarepta Therapeutics, was granted 16,875 restricted stock units (RSUs) on 2026-06-04 (reported on Form 4 filed 2026-06-05). The award is an equity grant (code A); no per-share price or total dollar amount is listed in the filing. RSUs represent the right to receive one share of common stock each upon vesting.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (appears timely).
• Transaction type/code: Grant/Award (A).
• Shares/units granted: 16,875 RSUs; price: N/A (grant).
• Shares owned following the transaction: Not specified in this filing.
• Footnote: RSUs vest on the earlier of the one‑year anniversary of the grant date and the next annual meeting of stockholders that is at least 50 weeks after the prior meeting.
• No indication of a 10b5-1 plan, sale, exercise, or tax‑withholding reported in this Form 4.

Context RSU grants to directors are a common form of compensation and do not represent an immediate market purchase or sale — they convert to shares only when vested. To estimate the grant’s market value, multiply 16,875 by Sarepta’s share price on or shortly after 2026-06-04. The filing itself is factual and does not state any intent or market sentiment.